Inari Medical, Inc., a pioneering commercial-stage medical device company dedicated to advancing the treatment of venous diseases, has successfully raised an impressive $4.9 billion in its latest funding round. This substantial investment underscores the growing recognition of Inari Medical's innovative approach to transforming patient care within the vascular health sector. By designing cutting-edge products that address unmet needs in the treatment of various venous conditions, Inari Medical positions itself at the forefront of a vital healthcare niche. The funding will be strategically allocated to accelerate the development and launch of new technologies aimed at enhancing the quality of life for patients afflicted with these debilitating diseases. Furthermore, this capital will bolster research and development efforts, allowing the company to expand its product portfolio and reach more patients who can benefit from improved therapies. As the demand for effective solutions for venous disease continues to rise, Inari Medical is poised to innovate and lead with its commitment to excellence in medical device manufacturing. The successful fundraising round is a testament to the company’s strong market position and the confidence investors have in its future prospects to deliver life-changing solutions. With this significant influx of capital, Inari Medical is excited to embark on the next phase of its journey towards revolutionizing the treatment paradigm for venous diseases, ultimately ensuring that more patients receive the care they deserve.
Inari Medical Secures $490 Million Funding to Revolutionize Venous Disease Treatments
Get the full Inari Medical company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Kelso Group Holdings Plc
Kelso will identify, engage and unlock trapped value in UK listed companies. Through active engagement and alignment with other stakeholders, taking stakes directly, Kelso aims to effect change where existing shareholders are often unable or unwilling to do so themselves.
$819.0K Unknown
today
LawX
LawX ist das Betriebssystem der nächsten Generation für Notariate und Kanzleien. Von der Anlage bis zur Abrechnung vereint LawX alle Arbeitsschritte in einem intelligenten, KI-gestützten System. Das Ergebnis: schnelleres, produktiveres Arbeiten mit mehr Effizienz und weniger Aufwand. LawX ist intuitiv aufgebaut, sofort verständlich und vom ersten Tag mit den eigenen Büro-Vorlagen nutzbar – ganz ohne lange Schulungen oder komplexes Programmieren. KI-basierte Automatisierung übernimmt Routineaufgaben präzise und verlässlich. So wächst das Büro weiter, auch wenn Fachkräfte knapp sind. Mit LawX behalten Teams jederzeit den Überblick, arbeiten reibungslos zusammen und sichern Qualität und Exzellenz in jedem Schritt.
$7.5M Seed
today
Rendesco
Rendesco is the UK’s leading clean energy tech developer and operator, focusing on the electrification of heat using heat pumps and heat networks to decarbonise Britain’s buildings. We design, install, and manage clean heat solutions which transfer heat from below the surface of the Earth to provide homes and buildings with sustainable heat and hot water. We currently own and manage over 70 ground source networks and provide heat to more than 3,000 homes in the UK. Since launching in 2012, we have developed a unique and highly efficient solution for decarbonising homes and buildings. Each property we serve saves 18 tonnes of Co2 compared to a gas boiler and three tonnes of Co2 compared to an air source heat pump. We have curated a team of 30 highly-technical experts, merging experience from the investment, property, construction and renewable energy industries to create a unique business model and deliver a solution to the UK’s clean heat challenge. Heat networks need technical know-how and we have the most experience - and the best reputation - in the UK. To find out more and get in touch, click the link to our website above.
$126.0M Unknown
today
Bona Investment & Management Co.
Bona Investment & Management Co. is the Platform to unite investors with the businesses, to create bona fide opportunities for both sides. Bona implements and achieves the optimum in M&A, Spin–off, Debt financing, Financial restructuring, Strategic Partnership, Business Development, Business Streamlining, Investment, Management & Operational needs of its clients. Bona’s trademark assessment algorithm tool called TIBA helped many clients find the right solutions in their business needs/decisions in the fields of: Energy & Chemicals, FMCG, Logistics, Healthcare, Pharmaceutical & Medical Devices, Information & Mobile Technology, Real Estate, Aviation, Insurance, Automotive, Retail, Hotel & Tourism, Durables, Education, Marina/Port and Shipping. Penetrated into North America, Europe, Russia, Middle-East and Asia-Pacific regions, Bona serves its clients with its highly experienced Team Members and Partners, from their offices in Turkey and Netherlands. Please visit www.thebona.net for more detailed information.
$25.3M Series b
today
Violet Therapeutics
Violet Therapeutics is a pre-clinical stage company leveraging a first-in-class platforms to identify, map and mine cell-to-cell communication at scale. Violet’s drug discovery programs are focused on CNS diseases enabled by the novel targets elucidated by their platforms. Violet was co-founded in 2021 by Mass General Brigham Ventures and scientists from Brigham & Women’s Hospital.
$4.8M Seed
today